Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombocytopenic, Idiopathic | 12 | 2026 | 52 | 4.570 |
Why?
|
| Thrombocytopenia | 6 | 2026 | 223 | 1.400 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 4 | 2026 | 29 | 1.210 |
Why?
|
| Anemia, Megaloblastic | 2 | 2019 | 4 | 1.200 |
Why?
|
| Immunoglobulins, Intravenous | 3 | 2025 | 142 | 1.080 |
Why?
|
| Transportation | 1 | 2024 | 27 | 0.880 |
Why?
|
| Autoimmune Diseases | 3 | 2023 | 264 | 0.880 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 199 | 0.810 |
Why?
|
| Eosinophilia | 2 | 2022 | 103 | 0.780 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 147 | 0.770 |
Why?
|
| Thiamine Deficiency | 1 | 2019 | 3 | 0.610 |
Why?
|
| Hydroxocobalamin | 1 | 2018 | 9 | 0.580 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 348 | 0.570 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 49 | 0.550 |
Why?
|
| Child, Preschool | 18 | 2026 | 14316 | 0.540 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1715 | 0.540 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 154 | 0.530 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 157 | 0.530 |
Why?
|
| Osteosarcoma | 1 | 2019 | 258 | 0.500 |
Why?
|
| Adolescent | 19 | 2026 | 19904 | 0.480 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2025 | 31 | 0.480 |
Why?
|
| Child | 24 | 2026 | 25015 | 0.470 |
Why?
|
| Infant | 12 | 2025 | 12758 | 0.460 |
Why?
|
| Rho(D) Immune Globulin | 3 | 2025 | 13 | 0.450 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 425 | 0.440 |
Why?
|
| Exercise | 3 | 2025 | 832 | 0.440 |
Why?
|
| Thrombosis | 1 | 2019 | 494 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 786 | 0.410 |
Why?
|
| Disease Progression | 1 | 2018 | 2102 | 0.370 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 874 | 0.340 |
Why?
|
| Male | 22 | 2026 | 61966 | 0.340 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2025 | 332 | 0.320 |
Why?
|
| Female | 22 | 2026 | 67790 | 0.320 |
Why?
|
| Humans | 33 | 2026 | 125613 | 0.310 |
Why?
|
| Prognosis | 5 | 2025 | 4668 | 0.270 |
Why?
|
| Benzoates | 1 | 2025 | 23 | 0.240 |
Why?
|
| Hydrazines | 1 | 2025 | 29 | 0.240 |
Why?
|
| Thiophenes | 1 | 2025 | 67 | 0.230 |
Why?
|
| Thiazoles | 1 | 2025 | 97 | 0.230 |
Why?
|
| Missouri | 1 | 2024 | 41 | 0.220 |
Why?
|
| Chronic Disease | 3 | 2024 | 1176 | 0.220 |
Why?
|
| Immunoglobulins | 1 | 2024 | 156 | 0.210 |
Why?
|
| Social Stigma | 1 | 2024 | 78 | 0.200 |
Why?
|
| Pyrazoles | 1 | 2025 | 312 | 0.200 |
Why?
|
| Transgender Persons | 1 | 2024 | 63 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 43 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2023 | 50 | 0.190 |
Why?
|
| Thrombocytosis | 1 | 2022 | 33 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 51 | 0.180 |
Why?
|
| Adult | 9 | 2024 | 30189 | 0.180 |
Why?
|
| Neutropenia | 2 | 2019 | 198 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 222 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16725 | 0.170 |
Why?
|
| Platelet Count | 3 | 2025 | 129 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12334 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2022 | 192 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 733 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 218 | 0.160 |
Why?
|
| Coombs Test | 1 | 2019 | 6 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2019 | 53 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 3645 | 0.150 |
Why?
|
| Fatigue | 1 | 2020 | 194 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 85 | 0.150 |
Why?
|
| Genotype | 1 | 2024 | 2597 | 0.150 |
Why?
|
| Radiotherapy | 1 | 2019 | 124 | 0.140 |
Why?
|
| Hematologic Tests | 1 | 2018 | 36 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 121 | 0.140 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2018 | 44 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 80 | 0.140 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 181 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 104 | 0.140 |
Why?
|
| Failure to Thrive | 1 | 2018 | 88 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 102 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 171 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2024 | 1518 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2018 | 177 | 0.140 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2017 | 6 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 141 | 0.140 |
Why?
|
| Histiocytes | 1 | 2017 | 18 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2019 | 364 | 0.130 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2017 | 30 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 100 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2018 | 378 | 0.130 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 73 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2017 | 71 | 0.130 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 678 | 0.130 |
Why?
|
| Heart Atria | 1 | 2019 | 327 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2018 | 285 | 0.120 |
Why?
|
| Rituximab | 1 | 2017 | 164 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 526 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 2016 | 84 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1228 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 2742 | 0.120 |
Why?
|
| Bacteremia | 1 | 2019 | 419 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 151 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 370 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 387 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 483 | 0.110 |
Why?
|
| Sports | 2 | 2025 | 61 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 290 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 3248 | 0.100 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 222 | 0.100 |
Why?
|
| Neoplasms | 2 | 2018 | 2814 | 0.100 |
Why?
|
| Age Factors | 1 | 2018 | 2757 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1223 | 0.090 |
Why?
|
| HIV Infections | 1 | 2022 | 1955 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2917 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2009 | 38 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2018 | 3414 | 0.080 |
Why?
|
| Middle Aged | 3 | 2024 | 27263 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2009 | 110 | 0.070 |
Why?
|
| Disease Management | 2 | 2024 | 528 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 253 | 0.060 |
Why?
|
| Mutation | 1 | 2019 | 5907 | 0.060 |
Why?
|
| North America | 1 | 2026 | 248 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 381 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 687 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5079 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2025 | 677 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2025 | 353 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2024 | 221 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Lamivudine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3295 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2025 | 466 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 228 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2022 | 246 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 244 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 122 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2025 | 6162 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 646 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2022 | 312 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2026 | 3884 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 610 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2026 | 1058 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 15 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2017 | 31 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 298 | 0.030 |
Why?
|
| United States | 2 | 2025 | 11141 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 191 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1415 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2007 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 225 | 0.030 |
Why?
|
| Risk Factors | 2 | 2022 | 10346 | 0.030 |
Why?
|
| Young Adult | 2 | 2025 | 9556 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 902 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2558 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 527 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1380 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2896 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 2041 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1068 | 0.020 |
Why?
|
| Phenotype | 1 | 2020 | 4295 | 0.020 |
Why?
|
| Arkansas | 1 | 2009 | 58 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 279 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3531 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8362 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2507 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 4446 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 19970 | 0.010 |
Why?
|